Susceptibility testing of Anopheles malaria vectors with the neonicotinoid insecticide clothianidin; results from 16 African countries, in preparation for indoor residual spraying with new insecticide formulations

Richard M. Oxborough,Aklilu Seyoum,Yemane Yihdego,Roch Dabire,Virgile Gnanguenon,Francis Wat’senga,Fiacre R. Agossa,Gedeon Yohannes,Sylvester Coleman,Lazarus Musa Samdi,Abdoulaye Diop,Ousmane Faye,Stephen Magesa,Alphaxard Manjurano,Michael Okia,Evelyne Alyko,Hieronymo Masendu,Ibrahima Baber,Arthur Sovi,Jean-Desire Rakotoson,Kenyssony Varela,Bernard Abong’o,Bradford Lucas,Christen Fornadel,Dereje Dengela
DOI: https://doi.org/10.1186/s12936-019-2888-6
2019-08-01
Malaria Journal
Abstract:In 2017, more than 5 million house structures were sprayed through the U.S. President's Malaria Initiative, protecting more than 21 million people in sub-Saharan Africa. New IRS formulations, SumiShield™ 50WG and Fludora Fusion™ WP-SB, became World Health Organization (WHO) prequalified vector control products in 2017 and 2018, respectively. Both formulations contain the neonicotinoid active ingredient, clothianidin. The target site of neonicotinoids represents a novel mode of action for vector control, meaning that cross-resistance through existing mechanisms is less likely. In preparation for rollout of clothianidin formulations as part of national IRS rotation strategies, baseline susceptibility testing was conducted in 16 countries in sub-Saharan Africa.
infectious diseases,tropical medicine,parasitology
What problem does this paper attempt to address?